$PROK

Pereira Brian JG sold $116K of PROK

Pereira Brian JG sold 81,929 shares of PROKIDNEY CORP. (PROK) at an average of $1.41 ($1.37–$1.44, $0.12M total) across 3 trades over 2026-08-18 to 2026-08-20.

Original reporting
SEC EDGAR · Pereira Brian JG
Published Aug 20, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PROK
Bearish
medium confidence
Mentioned
$PROK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PROKBearishLow
01

Why it matters

The disclosure provides fresh data on insider sentiment, but the transaction size is small relative to market cap.

02

Market read

New insider sell may cause slight bearish pressure; relevance limited.

03

What to watch

Potential tax planning or personal liquidity needs driving the sale.

Relevance 4/10Novelty 4/10Timing: filed today

Background

Form 4 filing discloses insider transactions; director exits position entirely.

Company-level read

Ticker impact

$PROKBearishMedium confidence
Context

Director Brian J. Pereira sold his entire 81,929-share stake for $115.5K, reducing holdings to zero.

Expected impact

Modest short-term downside as market digests the sell-off.

Evidence & confidence

The sale is a primary Form 4 filing but the dollar amount is modest; impact likely limited to sentiment.

Market effects

Minimal effect on the broader biotech/renal sector.

No notable regional impact.

Limited to investors tracking insider activity.

Counterpoint

The sale could be unrelated to company fundamentals; price may remain stable.

Key entities

  • PROKIDNEY CORP.

    Issuer of the Form 4 filing.

  • Brian J. Pereira

    Director who sold his shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PROKMed

ProKidney (PROK) Nears A Pivotal Kidney Therapy Verdict

ProKidney (NASDAQ:PROK) completed enrollment for a pivotal trial of its kidney disease therapy, with results expected in Q2 2027. R&D spending rose to $36.1M, widening losses to $46.4M. Cash reserves dropped to $181.6M, enough to last until mid-2027. Hedge fund holdings fell to 7 from 21, and short interest is 13.83% of the float.

$PROKMed

ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights

PROKIDNEY CORP. (PROK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights • Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results